Short answer
Ultherapy PRIME is the current console of the Ulthera System, a device that delivers microfocused ultrasound with visualisation (MFU-V: focused ultrasound energy guided by a live ultrasound image) to heat small points beneath the skin. In the United States it is cleared to lift the eyebrow, lift lax tissue under the chin and on the neck, and improve lines and wrinkles of the décolletage, with later clearance for the arms and abdomen.12 Studies report mostly mild to moderate improvement in mild to moderate laxity, not the degree of change a surgical facelift can produce.5 Because sagging has several causes, and not all of them involve the skin, whether this treatment makes sense depends on an in-person assessment.
Decision snapshot
| Question | Summary |
|---|---|
| What it is | Non-invasive focused ultrasound with real-time imaging to 8 mm depth |
| US-cleared uses | Brow lift; lax submental and neck tissue; décolletage lines; skin laxity of arms and abdomen |
| Typical candidate in studies | Mild to moderate laxity, mostly women, body mass index under 30 |
| Sessions studied | Usually one |
| Anaesthesia | None or local measures; no general anaesthesia |
| Pain during treatment | Moderate on average |
| Main limitation | Modest change; does not remove loose skin or replace lost volume |
| Overall evidence | Moderate for short-term facial improvement; mostly uncontrolled studies |
On this page
- What Ultherapy PRIME is and how it works
- What may be causing the concern
- Who may be considered
- Alternatives
- Procedure, preparation and anaesthesia
- Recovery and results timeline
- How long results last
- Pain and comfort
- Risks and complications
- How strong is the evidence?
- Device distinctions and red flags
- Cost drivers and what a quote should include
- Frequently asked questions
- Bottom line
- Sources
What Ultherapy PRIME is and how it works
Ultherapy is the treatment name for the Ulthera System, made by Ulthera, Inc. (part of Merz Aesthetics). PRIME refers to the UC-1 Control Unit PRIME console, which the US Food and Drug Administration (FDA) cleared in February 2024 through the 510(k) route, in which a device is judged substantially equivalent to one already on the market. The comparison device was the earlier Ulthera System, with the same face, neck and décolletage indications.1
The system has a control unit, a handpiece and interchangeable DeepSEE transducers (the heads placed on the skin). According to the manufacturer’s instructions for use, these focus energy at depths of 1.5 mm, 3.0 mm or 4.5 mm, depending on the transducer, and create small, separate points of heat-induced tissue coagulation.3 The same transducers show an ultrasound image of tissue to 8 mm deep. The FDA-cleared purpose of that image is to confirm the transducer is in proper contact with the skin and to confirm treatment depth, for example to avoid bone.2
The intended effect is gradual tightening as the body repairs those small heated points. In 2025 the FDA extended the cleared uses to the abdomen and upper arms, and cleared an updated PRIME console with a treatment-planning mode.24 This page focuses on the face, neck and décolletage.
What may be causing the concern
A heavier brow, softer jawline or looser neck can come from several layers at once. A review of facial ageing describes changes in bone, deep and superficial fat, the retaining ligaments, muscle and skin, each contributing to the overall look.12
- Skin: with age the skin becomes drier and less elastic, with less collagen and fat in its deeper layers; ultraviolet light and smoking speed this up.11
- Ligaments and fat: weakening retaining ligaments let tissue descend, contributing to jowls and folds, while deep fat compartments shrink.12
- Bone: the facial skeleton recedes and remodels, removing support for the tissue above it.12
- Muscle: repeated expressions create lines, and changes in muscle pull alter how the skin sits.1112
MFU-V acts mainly on the skin and the layers just beneath it. It does not rebuild bone or replace lost fat.
What it will not change
- Large amounts of loose or excess skin, which no non-surgical device removes.
- Volume loss from fat or bone changes.
- Severe laxity, where reviewers consider surgery the more likely option.6
- Ongoing ageing: any tightening is followed by the same processes that caused the laxity.
Who may be considered
Most published studies treated adults with mild to moderate laxity of the face and neck. One systematic review found that over 90% of participants were women and that results appeared weaker in people with marked laxity or a body mass index (BMI) above 30.6 Suitability depends on what is causing the change, skin quality, medical history and realistic expectations.
Who may not benefit or may face additional risk
- People with heavy skin excess or deep folds, where the expected change may be too small to notice.6
- Men, who are under-represented in the studies, so results are less certain.6
- People who are pregnant or breastfeeding, taking anticoagulants, or who have bleeding disorders, autoimmune disease, diabetes, epilepsy or Bell’s palsy: the manufacturer states the device has not been evaluated in these groups.3
When a responsible clinician may advise against it
- Open wounds, lesions, or severe or cystic acne in the area; active implants such as pacemakers, or metal implants in the area (listed contraindications).3
- Treatment directly over dermal fillers, breast implants or a keloid scar, which the labelling advises against.3
- When the concern is mainly volume loss or heavy skin excess, so a different approach fits the cause better.
Alternatives
| Option | What it addresses | Main trade-off |
|---|---|---|
| Facelift or neck lift | Sagging cheeks, jowls, neck skin and fat10 | Surgery, scars and longer recovery; does not treat fine lines or sun damage |
| Radiofrequency devices | Mild laxity through heating | Also modest effects; different discomfort and risk profile |
| Dermal fillers or biostimulators | Volume loss | Injectable risks; not a tightening treatment |
| Botulinum toxin | Expression lines | Does not lift lax tissue |
| Sun protection and not smoking | Slows further skin ageing11 | Preventive rather than corrective |
See also facelift and dermal fillers.
No treatment is a legitimate option
Skin laxity is a normal part of ageing, not a disease. Choosing to do nothing carries no medical risk.
Procedure, preparation and anaesthesia
Treatment is an outpatient procedure without incisions. The skin is cleaned and marked, ultrasound gel is applied, and the clinician uses the image to check skin contact and depth before delivering lines of energy.37 Treatment time depends on the number of areas.
General anaesthesia is not used. Comfort measures range from topical numbing cream to oral painkillers or local nerve blocks (see Pain and comfort). Preparation includes disclosing medicines, implants and previous filler treatments, because these affect where the device can be used.3
Recovery and results timeline
Most people go back to normal activity soon after. Redness, swelling, tenderness and bruising are the common early effects and are usually mild to moderate and temporary.58
Change is gradual, not immediate, and studies commonly assess results at about 90 days. In pooled data, the share of patients who saw improvement themselves rose from 42% at 90 days to 53% at one year, while investigators rated far more patients as improved.6
How long results last
Follow-up in most studies runs to about a year, and long-term data are limited.6 The effect is not permanent, because the skin, fat, ligaments and bone continue to age. Studies have mostly looked at a single session, so the value of repeat sessions is not well established.6
Pain and comfort
Most people feel the treatment. A 2024 meta-analysis pooling 785 patients found an average pain score of about 4.9 out of 10, described as moderate, and slightly lower on the face and neck than on the body.5 An earlier review reported about 3.8 out of 10.6
An expert panel agreed that expectations should be set beforehand and pain monitored during treatment. Individual panellists described options including topical anaesthetic cream applied around 20 minutes beforehand, oral painkillers, vibration distraction, local nerve blocks, lower energy settings and shorter sessions.7 Tenderness afterwards usually settles on its own.8
Risks and complications
Expected temporary effects
Redness, swelling, tenderness and bruising are common and mostly mild to moderate.5 Raised lines or welts along treatment lines can occur and usually fade.8
Recognised complications
Nerve irritation can cause temporary numbness, tingling or weakness of facial movement. One review reported uncommon effects, including altered sensation, bruising, skin striations and small burns, in about 2% of treated patients.68 Reviews attribute many surface burns to incorrect technique.8
Rare serious complications
Case reports and expert panels describe burns with scarring or pigment change, loss of fat under the skin (lipoatrophy), longer-lasting nerve injury and inflammation of the parotid salivary gland.7 A single case report described serious eye damage, including glaucoma and cataract, after treatment near the eye; its authors advise never directing the transducer towards the eye.9 How often these events occur is not known.
How strong is the evidence?
| Claim | Vireon assessment | What supports it | Important limitation |
|---|---|---|---|
| Produces mild to moderate short-term improvement in facial and neck laxity | Moderate | Two systematic reviews, 16 and 42 studies56 | Mostly before-and-after studies without control groups |
| Improves décolletage lines | Limited | FDA-cleared indication1 | Few independent studies |
| Results last beyond one year | Insufficient | Follow-up mostly up to 12 months6 | Very little long-term data |
| Comparable to a surgical facelift | Insufficient | No direct comparisons found6 | Reviewers suggest surgery for severe laxity |
| PRIME gives better results than earlier Ulthera consoles | Insufficient | FDA cleared it as equivalent to its predicate1 | No head-to-head outcome studies found |
| Treatment pain is moderate on average | Moderate | Pooled scores from 785 patients5 | Very high variation between studies |
| Serious burns, nerve or eye injury | Uncertain incidence | Case reports and expert consensus79 | Likely under-reported; no reliable rates |
The 2024 meta-analysis included 42 studies, but only two were controlled trials; it found signs of publication bias and was funded by the manufacturer.5 The safety review and the expert consensus also had manufacturer involvement.78 Independent, randomised, long-term studies are still needed.
Device distinctions and red flags
Many devices are sold as high-intensity focused ultrasound (HIFU), and not all have built-in imaging. In bench testing reported by an expert panel, the HIFU devices tested could not detect poor skin contact, whereas MFU-V displays an error.7 Ultherapy results should not be assumed for other devices.
- The device or transducers cannot be named or shown.
- Results are described as equal to a facelift.
- Treatment is offered on the eyelids or directed towards the eye.3
- No medical history is taken, or implants and fillers are not asked about.
Cost drivers and what a quote should include
Cost depends on the areas treated, the number of lines delivered, who performs the treatment, comfort measures and follow-up. A clear quote names the device and console, lists the areas, says who treats you, and states how complications are handled.
If you are travelling for treatment
- Laxity, its causes and any implants or fillers need in-person assessment before treatment.
- Treatment is usually a single outpatient visit; allow time to be seen again if redness, swelling or welts persist.
- We did not find specific published guidance on flying afterwards; ask the treating clinician.
- Results are usually judged at around three months, so plan how follow-up and any concerns will be handled from home.
Questions worth asking a clinician
- What do you think is causing my laxity, and how much of it can this treatment address?
- Which device and transducers will you use, and will you use the imaging?
- What options are there for pain control?
- How would a burn or nerve problem be managed, and by whom?
- Would a surgical or different non-surgical option suit my situation better?
Frequently asked questions
Does Ultherapy PRIME hurt?
Yes, most people report moderate discomfort during treatment.5 Numbing cream, painkillers or nerve blocks may reduce it.7
How soon will I look normal and be able to work?
Most people can return to work soon after, though redness, swelling or bruising may be visible for a short time.8 Exercise and driving usually depend on how you feel and whether any sedating medicine was given.
How many sessions are needed?
Most studies used a single session.6 Whether repeat sessions add benefit has not been well studied.
How long do results last?
Evidence mostly covers up to about one year, and results are not permanent.6
Can it replace a facelift?
No. It is studied for mild to moderate laxity, while a facelift addresses sagging tissue surgically.610
Bottom line
Ultherapy PRIME is a newer console for an established ultrasound treatment, not a new kind of result. For mild to moderate laxity it may give a small, gradual change, at the cost of moderate pain and a low but real risk of burns or nerve effects. When sagging comes mainly from volume loss or heavy skin excess, other approaches fit the cause better.
Related reading
Sources
- US Food and Drug Administration. 510(k) premarket notification K233996: Ulthera System (UC-1 Control Unit PRIME). FDA; 2024. https://www.accessdata.fda.gov/cdrh_docs/pdf23/K233996.pdf. Accessed 5 November 2026.
- US Food and Drug Administration. 510(k) premarket notification K243035: Ulthera System. FDA; 2025. https://www.accessdata.fda.gov/cdrh_docs/pdf24/K243035.pdf. Accessed 5 November 2026.
- Ulthera, Inc. Ulthera System instructions for use (DeepSEE technology for Ultherapy PRIME). Merz Aesthetics; 2025. https://merzaesthetics.com/app/uploads/2025/11/ultherapy-prime-instructions-for-use.pdf. Accessed 5 November 2026.
- US Food and Drug Administration. 510(k) premarket notification K250418: Ulthera System (UC-1 Control Unit PRIME Model 2.1). FDA; 2025. https://www.accessdata.fda.gov/cdrh_docs/pdf25/K250418.pdf. Accessed 5 November 2026.
- Amiri M, Ajasllari G, Llane A, et al. Microfocused ultrasound with visualization (MFU-V) effectiveness and safety: a systematic review and meta-analysis. Aesthetic Surgery Journal; 2024. doi:10.1093/asj/sjae228. https://pmc.ncbi.nlm.nih.gov/articles/PMC11834976/
- Contini M, Hollander MHJ, Vissink A, et al. A systematic review of the efficacy of microfocused ultrasound for facial skin tightening. International Journal of Environmental Research and Public Health; 2023. doi:10.3390/ijerph20021522. https://pmc.ncbi.nlm.nih.gov/articles/PMC9861614/
- Pavicic T, Ballard JR, Bykovskaya T, et al. Microfocused ultrasound with visualization: consensus on safety and review of energy-based devices. Journal of Cosmetic Dermatology; 2022. doi:10.1111/jocd.14666. https://doi.org/10.1111/jocd.14666
- Hitchcock TM, Dobke MK. Review of the safety profile for microfocused ultrasound with visualization. Journal of Cosmetic Dermatology; 2014. doi:10.1111/jocd.12111. https://pubmed.ncbi.nlm.nih.gov/25399626/
- Rechuan MM, Vaz JC, Marques FDAP, Azulay DR. Ophthalmological complications related to the use of microfocused ultrasound in the periocular region and face. Anais Brasileiros de Dermatologia; 2023. doi:10.1016/j.abd.2021.12.013. https://pmc.ncbi.nlm.nih.gov/articles/PMC10589498/
- Mayo Clinic. Face-lift. Mayo Foundation for Medical Education and Research. https://www.mayoclinic.org/tests-procedures/face-lift/about/pac-20394059. Accessed 5 November 2026.
- Mayo Clinic. Wrinkles: symptoms and causes. Mayo Foundation for Medical Education and Research. https://www.mayoclinic.org/diseases-conditions/wrinkles/symptoms-causes/syc-20354927. Accessed 5 November 2026.
- Swift A, Liew S, Weinkle S, Garcia JK, Silberberg MB. The facial aging process from the “inside out”. Aesthetic Surgery Journal; 2021. doi:10.1093/asj/sjaa339. https://pmc.ncbi.nlm.nih.gov/articles/PMC8438644/
Article history
- — First published.